Palisade Bio surges 39% on fast track tag for post surgery gastrointestinal therapy

Nov. 22, 2022 9:10 AM ETPalisade Bio, Inc. (PALI)By: Dania Nadeem, SA News Editor

Growth arrow up and progress success business skill increase improvement graph on market profit stock background with goal of achievement futuristic finance economy.


  • Palisade Bio (NASDAQ:PALI) said on Tuesday the U.S. Food and Drug Administration had granted Fast Track designation to LB1148, used for the acceleration of time to return of bowel function following gastrointestinal surgery.
  • (PALI) is trading ~39% higher premarket.
  • Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fulfill an unmet medical need.
  • LB1148, is a protease inhibitor which acts to neutralize digestive enzymes, with the potential to both reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.